10Y annualized return is
very good
at 10.5% per year
ABT has met or exceeded earnings expectations in
the majority of
recent quarters (8/10)
Attractive P/E Ratio
Reasonable Price-to-Sales Ratio
High P/FCF Ratio
Elevated EV/EBITDA Ratio
Get access to all key takeaways, detailed financial metrics, and comprehensive stock analysis with our premium subscription.
Already have an account? Sign in
Overall, Abbott Laboratories demonstrates a strong business quality driven by a diversified model and a commitment to innovation. While it faces challenges in specific segments like diagnostics, its future prospects remain bright with a robust pipeline and growth in medical devices. However, external factors such as tariffs and economic uncertainties may pose risks to its growth trajectory.
Analysis Date: April 16, 2025
Last Updated: May 29, 2025
Past performance does not guarantee future results. The data presented is indicative and may not be updated in real-time.
Abbott Laboratories is a healthcare company that makes a wide range of products to help people stay healthy. They create things like medications for various illnesses, medical devices for heart and diabetes care, and nutritional products for babies and adults. Abbott also provides testing equipment that helps doctors diagnose diseases quickly. Founded in 1888, the company is based in North Chicago, Illinois, and works to improve health around the world.
Core Products
Business Type
Business to Business
Competitive Advantages
Discover all competitive advantages and strategic moats that protect ABT's market position.
View Premium AnalysisKey Business Risks
Get comprehensive insight into all key business risks that could impact ABT's performance.
Access Full Risk AnalysisLatest News
ABT continues to offer a compelling high-growth investment thesis, driven by the GLP-1 tailwinds on its Continuous Glucose Monitoring and adult nutrit...
Abbott Laboratories ABT reported better-than-expected first-quarter adjusted EPS results on Wednesday.
Live Updates Live Coverage Has Ended S&P Sinks 3% in Tech-Fueled Sell-Off 3:21 pm by Gerelyn Terzo Technology stocks are in freefall mode, sending...
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Benjamin Graham's value investing approach focuses on finding stocks with a significant margin of safety between their intrinsic value and market price.
Access Benjamin Graham's value investing criteria, intrinsic value calculations, and margin of safety analysis
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Profitability metrics measure a company's ability to generate earnings relative to its revenue, operating costs, and other relevant metrics. Higher values generally indicate better performance.
Access detailed profitability metrics with visual gauges and benchmarks
Access detailed analysis of profitability strengths and positive performance indicators
Upgrade to PremiumAccess detailed analysis of profitability weaknesses and areas of concern
Upgrade to PremiumFinancial health metrics assess a company's ability to meet its financial obligations and its overall financial stability.
Access detailed financial health metrics with visual gauges and risk assessments
Access detailed analysis of financial health strengths and stability indicators
Upgrade to PremiumAccess detailed analysis of financial health weaknesses and risk factors
Upgrade to PremiumMeeting Expectations
Higher values indicate better execution and credibility
Recent Results
View complete earnings history and detailed performance analysis
Upgrade to PremiumEPS
Revenue
Insider trading data shows purchase and sale activities by company executives and board members.
Insider trading patterns can provide insights into how company executives and board members view the stock's future prospects.
Get complete insider sentiment analysis with detailed trading patterns, sentiment indicators, and trend insights